Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
Provention Bio Inc (NASDAQ:PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated…
Provention Bio Reports Interim Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate: ‘was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers’
PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers
Positive data supports further development activities
RED BANK, N.J., Oct.
Precigen Posts Additional Interim Data From Type 1 Diabetes Trial
Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes…
Provention Bio Provides Update On Potential Timing Of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
Company working with the U.S. FDA to finalize the design of population PK model to be used to analyze substudy data and plans to
Provention Bio Says Is Working Towards Request And Submission To Allow Type A Meeting To Occur In Q4
Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address
Oppenheimer Maintains Outperform on Provention Bio, Lowers Price Target to $16
Oppenheimer maintains Provention Bio (NASDAQ:PRVB) with a Outperform and lowers the price target from $18 to $16.
HC Wainwright & Co. Maintains Buy on Provention Bio, Lowers Price Target to $25
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Provention Bio (NASDAQ:PRVB) with a Buy and lowers the price target from $27 to $25.
CORRECTION: Provention Bio Q2 EPS $(0.46) Beats $(0.52) Estimate
Provention Bio (NASDAQ:PRVB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 2.22 percent decrease over losses of $(0.45) per share from the
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)